       Document 0377
 DOCN  M9590377
 TI    The health care costs of HIV infection.
 DT    9509
 AU    Hurley S; Kaldor J; Department of Biostatistics, University of
       Washington, Seattle; 98115, USA.
 SO    Annu Conf Australas Soc HIV Med. 1994 Nov 3-6;6:112 (unnumbered
       abstract). Unique Identifier : AIDSLINE ASHM6/95291722
 AB    OBJECTIVE. To estimate rates of health service usage and costs for
       Australian men in different phases of HIV infection, and the lifetime
       cost attributable to HIV. METHODS. A prospective survey of 20 men in
       Phase 1 (CD4+ > or = 500 x 10(6)/l), 31 in Phase 2 (CD4+ < 500 x 10(6)/l
       and > or = 200 x 10(6)/l), 30 in Phase 3 (CD4+ < 200 x 10(6)/l), and 47
       in Phase 4 (AIDS). Lifetime cost was calculated by linking monthly costs
       and phase duration data. RESULTS. Health care was community-based in
       Phases 1 and 2 and hospital-based in Phases 3 and 4. Use of most health
       services was greater in more advanced phases. Mean monthly costs (1992
       dollars) were $331 (95% CI $218-455) in Phase 1, $677 (95% CI $540-836)
       in Phase 2, $1372 (95% CI $1044-1776) in Phase 3, $4615 (95% CI
       $3456-5985) for AIDS patients who did not die during the survey, and
       $13,308 (95% CI 10,538-16,516) for AIDS patients who died. The mean
       present value of lifetime cost for a patient diagnosed at the start of
       Phase 2 was around $93,000, of which 49% was for drugs and 32% was for
       hospital bed-days. CONCLUSION. Monthly health care costs increased with
       severity of illness, and were particularly high for AIDS patients within
       three months of death. The lifetime cost of HIV infection in Australia
       is higher than in the United States.
 DE    Acquired Immunodeficiency Syndrome/CLASSIFICATION/*ECONOMICS  Ambulatory
       Care/ECONOMICS  Australia  Costs and Cost Analysis  Health Care
       Costs/*TRENDS  Human  HIV Infections/CLASSIFICATION/*ECONOMICS  Male
       Patient Admission/ECONOMICS  Prospective Studies  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

